Joint injections Scottsdale: what may ease a sore joint

What may be causing the soreness?

Years of use can thin cartilage and leave a joint stiff or tender. Soreness may ease briefly, then return after more use.

Arthritis often feels worse after rest, then eases as you move gently. It may flare again after a full day on your feet.

Inflammation means the joint lining is irritated, which may cause warmth and swelling. You might notice both after extra work or a longer walk.

A strained tendon often hurts during one motion, such as lifting or climbing stairs. Your doctor can tell whether that fits and what to do next.

What can you try at home?

Slow, comfortable motion may keep a stiff joint from tightening further during the day. Please stop before that motion brings sharp soreness in the joint.

A brace may support your knee during errands or a comfortable walk. Ice or mild warmth may soothe the area for a short while.

Anti-inflammatory medicine means a drug such as ibuprofen or naproxen that reduces swollen tissue and joint aches. It isn’t safe with every health problem or pill.

A doctor or pharmacist who knows your medicines can check for harmful drug effects. You’ll want that check before adding one for your safety.

Notice which tasks raise the ache and how soon it eases afterward. Those brief notes can make your office talk more useful.

When is it worth getting looked at?

It’s worth arranging an exam when the ache returns often or limits things you value. You’re also welcome to call when rest and gentle care aren’t helping.

Please seek quick care if a fever comes with strong joint heat or swelling. Don’t wait if you cannot stand or take steps.

New weakness, numbness, or a joint with a new bent shape also needs attention. Those symptoms aren’t part of an ordinary ache after simple activity.

During a regular visit, the doctor asks about the first soreness and examines movement, strength, warmth, and swelling. You’ll have unhurried time for questions about each option.

Sources

1. A 2022 BMJ systematic review and meta-analysis of 169 trials (21,163 participants) found viscosupplementation produced only a small pain reduction versus placebo (SMD -0.08, 95% CI -0.15 to -0.02; about -2.0 mm on a 100 mm VAS), below the minimal clinically important difference, and trial sequential analysis indicated conclusive evidence of clinical equivalence with placebo since 2009.

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

2. A 2025 network meta-analysis restricted to LARGE randomized trials (57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials; excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6, while hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11) and higher odds of dropouts due to adverse events (OR 2.01) and serious adverse events (OR 1.86) than placebo.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

3. The 2025 Cochrane living review of stem cell injections for knee OA (25 trials, 1,341 participants) found stem cell injection MAY slightly improve pain and function up to six months versus placebo (pain 1.2 points better on a 0-10 scale; function 14.2 points better on 0-100), but rated the evidence LOW certainty for both, downgraded for indirectness and suspected publication bias, with up to three larger RCTs withdrawn before reporting results.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database Syst Rev, 2025. DOI: 10.1002/14651858.CD013342.pub2.

4. The RUbICOn mixed-methods HTA study, commissioned specifically to address uncertainty about recurrent injections, combined a UK primary-care cohort (2005-2020) linked to hospital data with a safety analysis, patient and clinician interviews, and a three-round Delphi to set research priorities - the current formal acknowledgement that the long-term risks and benefits of repeat injections remain unresolved.

   Whitehouse MR, et al. — RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study.. Health Technol Assess, 2025. DOI: 10.3310/LFAJ9337.